Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Jahr

2023

Autoren

Coles AJ, Achiron A, Traboulsee A, Singer BA, Pozzilli C, Oreja-Guevara C, Giovannoni G, Comi G, Freedman MS, Ziemssen T, Shiota D, Rawlings AM, Wong AT, Chirieac M, Montalban X.

Verlag

Ther Adv Neurol Disord. 2023 Sep 21;16:17562864231194823.

Link

https://doi.org/10.1177/17562864231194823

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Beyond B Cell Depletion: Adhesion and Activation Network Remodeling During Repeated Intravenous Anti-CD20 Therapy in Multiple Sclerosis

Jump assessment on a force plate—an approach to quantify subtle lower limb neuromuscular deficits in people with multiple sclerosis

Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries

Patient profiling in relapsing multiple sclerosis: insights from a real-world observational study into the unmet medical needs of patients on disease-modifying therapy

Immersive Virtual Reality Assessment in Multiple Sclerosis: Patient-Reported Experience and Correlates